Research
Hormonal
GLP-1 receptor (GLP-1R) agonists significantly reduce the occurrence of major adverse cardiovascular events in individuals with type 2 diabetes (T2D).
Practitioners should consider GLP-1R agonists as a therapeutic option for reducing cardiovascular risks in T2D patients.
StrongSupportsmedium confidence
Data from several cardiovascular outcome trials for GLP-1 receptor (GLP-1R) agonists have demonstrated significant reductions in the occurrence of major adverse cardiovascular events in individuals with T2D.
Why this rating
Based on data from several cardiovascular outcome trials.
Source
Incretin-mediated control of cardiac energy metabolism
Jordan S. F. Chan et al. · Journal of Endocrinology · 2024
reviewCited 1×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →